Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab

Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab

Abstract Background The optimal treatment sequence for patients with advanced BRAF V600 mutant melanoma is unknown. BRAF/MEK inhibition (BRAF/MEKi), single agent anti‐PD‐1 (aPD‐1) antibodies and combination immune checkpoint inhibition with nivolumab and ipilimumab (niv/ipi) are all approved; howeve...

Full description

Bibliographic Details
Main Authors:	Justin C. Moser, Danli Chen, Siwen Hu‐Lieskovan, Kenneth F. Grossmann, Shiven Patel, Sarah V. Colonna, Jian Ying, John R. Hyngstrom
Format:	Article
Language:	English
Published:	Wiley 2019-12-01
Series:	Cancer Medicine
Subjects:	anti‐PD‐1 antibodies BRAF dabrafenib melanoma nivolumab/ipilimumab pembrolizumab
Online Access:	https://doi.org/10.1002/cam4.2625

Similar Items

Lack of Influence of Non-Overlapping Mutations in <i>BRAF</i>, <i>NRAS</i>, or <i>NF1</i> on 12-Month Best Objective Response and Long-Term Survival after Checkpoint Inhibitor-Based Treatment for Metastatic Melanoma
by: Alyssa Panning, et al.
Published: (2023-07-01)

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
by: Wolfram Samlowski, et al.
Published: (2021-11-01)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
by: Ken Saijo, et al.
Published: (2022-08-01)

Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma
by: Samuel Rosner, et al.
Published: (2018-03-01)

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
by: Ascierto Paolo A, et al.
Published: (2012-05-01)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
by: Gulietta M. Pupo, et al.
Published: (2017-05-01)

BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation
by: Stefanie Hoyer, et al.
Published: (2021-11-01)

Secondary hemophagocytic lymphohistiocytosis due to nivolumab/ipilimumab in a renal cell cancer patient—A case report
by: Adeel Masood, et al.
Published: (2021-12-01)

Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution
by: Vincenzo Di Nunno, et al.
Published: (2023-01-01)

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
by: Karisa C. Schreck, et al.
Published: (2019-08-01)

Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma
by: David Balakirouchenane, et al.
Published: (2020-04-01)

Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
by: Mary Towner, et al.
Published: (2022-08-01)

Case report: Clinical success targeting BRAF-mutated, hormone receptor positive, HER2- negative advanced breast cancer patient with BRAF-inhibitor plus MEK- inhibitor
by: Alfonso López de Sá, et al.
Published: (2022-12-01)

BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways
by: Peng Yue, et al.
Published: (2019-01-01)

Effect of dabrafenib on melanoma cell lines harbouring the BRAF<sup><it>V600D/R</it></sup> mutations
by: Gentilcore Giusy, et al.
Published: (2013-01-01)

The best dosage of nivolumab plus ipilimumab combination for melanoma brain metastases
by: Takeshi Fukumoto, et al.
Published: (2022-08-01)

Immunotherapy and Cannabis: A Harmful Drug Interaction or Reefer Madness?
by: Brian J. Piper, et al.
Published: (2024-03-01)

BRAF L485–P490 deletion mutant metastatic melanoma sensitive to BRAF and MEK inhibition: A case report and literature review
by: Simeng Zhang, et al.
Published: (2023-01-01)

Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
by: Gabriele Madonna, et al.
Published: (2021-08-01)

BRAF Inhibitors in Non-Small Cell Lung Cancer
by: Vincenzo Sforza, et al.
Published: (2022-10-01)

Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod
by: Taku Fujimura, et al.
Published: (2018-01-01)

An Indirect Comparison Between Nivolumab + Ipilimumab + Two Cycles of Chemotherapy vs. Pembrolizumab + Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer
by: Panpan Jiang, et al.
Published: (2021-09-01)

Nivolumab with Ipilimumab in the treatment of refractory hepatocellular carcinoma
by: M. N. Khagazheeva, et al.
Published: (2022-06-01)

Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma
by: Taylor E. Woo, et al.
Published: (2023-09-01)

The Effect of Non-Overlapping Somatic Mutations in <i>BRAF</i>, <i>NRAS</i>, <i>NF1</i>, or <i>CKIT</i> on the Incidence and Outcome of Brain Metastases during Immune Checkpoint Inhibitor Therapy of Metastatic Melanoma
by: Wolfram Samlowski
Published: (2024-01-01)

Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review
by: Morena Fasano, et al.
Published: (2022-01-01)

Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis
by: Abdulaali R. Almutairi, et al.
Published: (2020-02-01)

Effectiveness Treatment of a BRAF-ZKSCAN5 Fusion Gene Melanoma Case with Dabrafenib/Trametinib
by: Hiroshi Kato, et al.
Published: (2023-09-01)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
by: Yoshito Nishimura, et al.
Published: (2018-08-01)

Outcome of Elective Checkpoint Inhibitor Discontinuation in Patients with Metastatic Melanoma Who Achieved a Complete Remission: Real-World Data
by: Leanne Perez, et al.
Published: (2022-05-01)

Cutaneous Melanoma versus Vulvovaginal Melanoma—Risk Factors, Pathogenesis and Comparison of Immunotherapy Efficacy
by: Anna Lorenz, et al.
Published: (2022-10-01)

Bronchiolitis Obliterans after Combination Immunotherapy with Pembrolizumab and Ipilimumab
by: Amulya Balagani, et al.
Published: (2018-07-01)

Bilateral multifocal central serous retinopathy due to management of metastatic melanoma with BRAf MEK inhibitors: Case report
by: Grisma Patel, et al.
Published: (2023-03-01)

Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations
by: Lucía Vázquez-Montero, et al.
Published: (2023-06-01)

<i>BRAF</i> V600E Detection in Liquid Biopsies from Pediatric Central Nervous System Tumors
by: Noemi García-Romero, et al.
Published: (2019-12-01)

Toxic Epidermal Necrolysis During Cotherapy with Ipilimumab and Nivolumab
by: Shelby L Kubicki, et al.
Published: (2018-10-01)

BRAF Mutant Melanoma Adjusts to BRAF/MEK Inhibitors via Dependence on Increased Antioxidant SOD2 and Increased Reactive Oxygen Species Levels
by: Long Yuan, et al.
Published: (2020-06-01)

Primary Pleural Angiosarcoma Treated with Nivolumab and Ipilimumab: A Case Report
by: Mikako Nakamura, et al.
Published: (2023-02-01)

Case Report: Response to ipilimumab and nivolumab in a patient with adrenocortical carcinoma
by: Rebecca Charles, et al.
Published: (2023-09-01)

Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany
by: S Wahler, et al.
Published: (2021-01-01)